Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001104659-26-056713
Filing Date
2026-05-07
Accepted
2026-05-07 08:09:48
Documents
55
Period of Report
2026-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q ewtx-20260331x10q.htm   iXBRL 10-Q 1696877
2 EX-10.1 ewtx-20260331xex10d1.htm EX-10.1 67589
3 EX-31.1 ewtx-20260331xex31d1.htm EX-31.1 19509
4 EX-31.2 ewtx-20260331xex31d2.htm EX-31.2 19295
5 EX-32.1 ewtx-20260331xex32d1.htm EX-32.1 7464
6 EX-32.2 ewtx-20260331xex32d2.htm EX-32.2 7496
  Complete submission text file 0001104659-26-056713.txt   5402651

Data Files

Seq Description Document Type Size
7 EX-101.SCH ewtx-20260331.xsd EX-101.SCH 27697
8 EX-101.CAL ewtx-20260331_cal.xml EX-101.CAL 30807
9 EX-101.DEF ewtx-20260331_def.xml EX-101.DEF 116033
10 EX-101.LAB ewtx-20260331_lab.xml EX-101.LAB 264794
11 EX-101.PRE ewtx-20260331_pre.xml EX-101.PRE 208298
59 EXTRACTED XBRL INSTANCE DOCUMENT ewtx-20260331x10q_htm.xml XML 729664
Mailing Address 1715 38TH ST BOULDER CO 80301
Business Address 1715 38TH ST BOULDER CO 80301 720-262-7002
Edgewise Therapeutics, Inc. (Filer) CIK: 0001710072 (see all company filings)

EIN.: 821725586 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40236 | Film No.: 26950976
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)